close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by LIB Therapeutics Inc.

News headline image
LIB Therapeutics Announces Results from Presentations on LEROCHOL® (lerodalcibep-liga) at the 2026 European Atherosclerosis Society Meeting in Athens, May 24-26, 2026
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026
From LIB Therapeutics Inc.
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Results from Late Breaking Science Presentation at 2025 American Heart Association Meeting in New Orleans November 9, 2025
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announce Positive Results from Lerodalcibep 72-Week Open-Label Extension Studies at American Heart Association 2024
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Lerodalcibep Abstracts Accepted for Presentation at the 92nd European Atherosclerosis Society Congress
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Appointment of Ingrid Choong, PhD as Chief Business Officer as Company Prepares BLA for Lerodalcibep
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion
From LIB Therapeutics Inc.
Via Business Wire
News headline image
LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial
From LIB Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today